Suppr超能文献

D-二聚体检测在接受口服抗凝剂治疗静脉血栓栓塞事件患者中的潜在应用。

Potential use of D-dimer measurement in patients treated with oral anticoagulant for a venous thromboembolic episode.

作者信息

Ombandza-Moussa E, Samama M M, Horellou M H, Elalamy I, Conard J

机构信息

Department of Biological Hematology, Hôtel Dieu Hospital, University of Paris, Paris, France.

出版信息

Int Angiol. 2003 Dec;22(4):364-9.

Abstract

AIM

We compared the level of plasma D-dimer in patients with previous venous thromboembolism (VTE), receiving or not oral anticoagulant treatment (OAT) and investigated its predictive value for the risk of VTE recurrence after OAT withdrawal.

METHODS

We have studied 149 patients, 81 receiving oral anticoagulants and 68 after treatment interruption. Patients with known causes of D-dimer increase were excluded. D-dimer measurements were performed by Vidas analyzer (bioMérieux, France).

RESULTS

A significantly lower D-dimer plasma level was found in patients under OAT than in untreated patients, 197+/-134 ng/ml versus 399+/-239 ng/ml, respectively (p<0.001). This decrease was similar in the different age populations and whether the patient had thrombophilia (n=84) or not. There was no correlation between INR and D-dimer levels. During a mean follow-up of 30 months, no recurrence occurred in patients under OAT versus 7 untreated patients. Among them, 3 had a D-dimer below 500 ng/ml, and 3 others had a level above 500 ng/ml. The last patient was not tested.

CONCLUSION

The physician should be informed of the decrease of D-dimer under OAT, since the usual cut-off of 500 ng/ml used for deep vein thrombosis (DVT) exclusion is probably lower in such treated patients. It has been recently proposed that normal D-dimer level had a high negative predictive value for VTE recurrence when this dosage was performed 3 months after OAT interruption. The small number of recurrences observed in our study with an available result of D-dimer measured more than 3 months after OAT discontinuation does not allow a definite

摘要

目的

我们比较了既往有静脉血栓栓塞症(VTE)且接受或未接受口服抗凝治疗(OAT)的患者血浆D - 二聚体水平,并研究了其对OAT停药后VTE复发风险的预测价值。

方法

我们研究了149例患者,其中81例接受口服抗凝剂治疗,68例在治疗中断后。排除已知导致D - 二聚体升高原因的患者。使用Vidas分析仪(法国生物梅里埃公司)进行D - 二聚体检测。

结果

接受OAT治疗的患者血浆D - 二聚体水平显著低于未治疗患者,分别为197±134 ng/ml和399±239 ng/ml(p<0.001)。在不同年龄人群中以及患者是否有血栓形成倾向(n = 84)时,这种下降情况相似。国际标准化比值(INR)与D - 二聚体水平之间无相关性。在平均30个月的随访期间,接受OAT治疗的患者无复发,而7例未治疗患者复发。其中,3例D - 二聚体低于500 ng/ml,另外3例高于500 ng/ml。最后1例患者未检测。

结论

应告知医生OAT治疗下D - 二聚体水平降低的情况,因为用于排除深静脉血栓形成(DVT)的通常临界值500 ng/ml在这类接受治疗的患者中可能更低。最近有人提出,在OAT中断3个月后进行此项检测时,正常D - 二聚体水平对VTE复发具有较高的阴性预测价值。在我们的研究中,观察到在OAT停药超过3个月后进行D - 二聚体检测且有可用结果时复发的病例数较少,无法得出明确结论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验